Allarity Therapeutics, Inc. (ALLR) - 10-Q Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company developing personalized cancer treatments using its proprietary Drug Response Predictor (DRP) technology. The company is focused on advancing its lead drug candidate, stenoparib. This report covers the quarterly period ended June 30, 2026. As of this date, the company had an accumulated deficit of $136.4 million and is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $25,000 | $0 |
| Net Loss | $(6,155,000) | $(5,052,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.39) | $(0.38) |
| Operating Expenses | $5,384,000 | $7,169,000 |
| Cash and Restricted Cash | $26,981,000 | $17,801,000 |
| Net Cash Used in Operating Activities | $(7,057,000) | $(8,167,000) |
| Total Debt (Current) | $20,862,000 | $0 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue: The company recognized $25,000 in license revenue for the six months ended June 30, 2026, compared to zero in the prior year period.
- Operating Expenses: Total operating expenses decreased by $1.8 million (25%) year-over-year. Research and Development (R&D) expenses dropped $1.1 million, and General and Administrative (G&A) expenses dropped $0.7 million, primarily due to reduced clinical trial costs and lower legal fees.
- Debt Financing: In March 2026, the company secured $20.0 million in gross proceeds via a Note Purchase Agreement with Streeterville Capital, LLC. This includes a $10.93 million unsecured A-1 Note and a $10.0 million secured B Note. Consequently, interest expense increased significantly to $948,000 for the six-month period compared to $69,000 in the prior year.
- Liquidity: Cash and restricted cash increased by $9.2 million to $26.9 million, driven by the new debt financing. However, $10.0 million of this cash is restricted to secure the B Note.
- Foreign Exchange: The company recorded a foreign exchange loss of $100,000 for the six months ended June 30, 2026, a reversal from a $1.7 million gain in the same period in 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that existing cash and restricted cash of $26.9 million will fund operations for at least the next twelve months. The company anticipates needing additional capital for future clinical trials and commercialization.
- Recent Developments: On July 7, 2026 (subsequent to the period end), the company announced CLIA certification for its in-house laboratory in Denmark, enabling in-house testing to accelerate stenoparib development.
- Risks:
- Debt Covenants: The Streeterville notes contain redemption rights and stock-price-based triggers that could accelerate repayment or increase obligations. A default could materially impair liquidity.
- Novartis Liability: Following a termination of a license agreement with Novartis in January 2024, the company has a recorded liability of approximately $5.6 million (including accounts payable, convertible notes, and accrued liabilities) which continues to accrue interest at 5% per annum.
- Going Concern: While the company currently meets the 12-month liquidity threshold, continued losses and the need for future financing present ongoing risks.
Investor Verification Checklist
- Debt Terms: Verify the specific stock-price triggers and redemption schedules for the Streeterville A-1 and B Notes to assess immediate liquidity risks.
- Novartis Liability: Confirm the current status of the $5.6 million liability from the terminated Novartis agreement and the impact of accruing interest on future cash flow.
- Restricted Cash: Note that $10.0 million of the reported cash balance is restricted and unavailable for general operations until the B Note is repaid or redeemed.
- Burn Rate: Monitor the trend in operating expenses, specifically R&D costs for stenoparib, to validate the 12-month runway estimate.
- Equity Line: Review the utilization of the $6.0 million equity line of credit with Tumim Stone Capital LLC, which remains largely unused ($5.998 million available).